This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Roden, D. M. Search for Related Content PubMed PubMed Citation Articles by Roden, D. M. Related Collections Other Ethics and Policy

(Circulation. 2005;111:246-248.)
© 2005 American Heart Association, Inc.

Editorial

An Underrecognized Challenge in Evaluating Postmarketing Drug Safety

Dan M. Roden, MD

From the Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tenn.

Correspondence to Dan M. Roden, MD, Director, Oates Institute for Experimental Therapeutics, Vanderbilt University School of Medicine, 532 Medical Research Building I, Nashville, TN 37232. E-mail dan.roden@vanderbilt.edu

Key Words: Editorials • drugs • pharmacology • complications • morbidity

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
The withdrawal of the cyclooxygenase (COX)-2–specific inhibitor rofecoxib (Vioxx; Merck) has generated a high-profile debate in the medical and lay press over when a signal suggesting the potential for harm from this drug was first apparent and what steps the medical community, the US Food and Drug Administration, and the pharmaceutical sponsor took and should have taken to address this issue.^1,2 This debate, however, has glossed over a fundamental problem that the withdrawal of the drug serves to highlight—not how best to deal with a potential signal once it is described, but rather how to identify such important and initially unanticipated effects after a drug is marketed.

	What Is Known About a Drug When It Is Marketed?

 
The contemporary processes of drug discovery and marketing include both basic studies and drug exposure in humans, generally in no more than several thousand patients. These studies establish a putative mechanism of action of the new compound, although, as discussed below, new molecular mechanisms of actions often are discovered after a drug has been marketed. Efficacy must be established in rigorous controlled clinical trials, with well-defined patient populations, inclusion and exclusion criteria, predefined end points, and appropriate statistical analyses. Other important pieces of information include major mechanisms of drug metabolism and excretion and the potential for both pharmacokinetic and pharmacodynamic drug interactions. An important result of this premarketing workup is that adverse effects that commonly occur during the administration of a drug become well recognized. If these effects are common or serious, then the drug may in fact not be suitable for marketing.

	What Is Not Known About a Drug When It Is Marketed?

 
. . . [Full Text of this Article]